“I think that growth is going to continue into this year.”

In context

“hose lines. To sort of explain that. Ed Milperant, I think, is an underappreciated story that was maybe negatively impacted by comparisons to a competitor asset. There's just a whole host of opportunities here that we see in the overall story this year. Hoping you might be able to help position some of those for us as we move through the balance of the year. Thanks so much. Christopher Boerner: Thanks for the question, Seamus. And agree with the overall sentiment. And maybe I will start and then I'll turn it over to Cristian Massacesi and Adam Lenkowsky and they can provide their perspectives. I think that when we look at what's particularly exciting for this year, I would highlight a few things. First of all, we've got good growth just in the products that we have on the market today and I think that growth is going to continue into this year. As you know, we have a slew of data readouts coming this year, now just a few months away. For six products. And when you look at the actual number of phase threes, we could have over 10 Phase three data readouts this year alone with more coming in '27 and then another big slew of them coming in 2028. The things that I think stand out for me, you've already mentioned them actually. The CELMoD program is beginning to bear fruit. We've already demonstrated PFS data for iverdemide. We'll see follow-up data on that with PFS this year. We've got admiral burn data coming. We've got the Melvexian data and I agree also with your assessment of that where you know, I think we'll see the SSP data from a competitor today. But as I look at our profile, I think we have the potential to be best in class”